• Publications
  • Influence
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
BACKGROUND Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C. Expand
  • 2,830
  • 91
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
BACKGROUND In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustainedExpand
  • 1,451
  • 46
  • Open Access
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
CONTEXT Chronic hepatitis C virus (HCV) infection outcomes include liver failure, hepatocellular carcinoma (HCC), and liver-related death. OBJECTIVE To assess the association between sustainedExpand
  • 1,209
  • 40
  • Open Access
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.
BACKGROUND & AIMS We recently identified a polymorphism upstream of interleukin (IL)-28B to be associated with a 2-fold difference in sustained virologic response (SVR) rates to pegylatedExpand
  • 727
  • 34
  • Open Access
Resistance to direct antiviral agents in patients with hepatitis C virus infection.
Chronic hepatitis C virus (HCV) infection is one of the major causes of cirrhosis, hepatocellular carcinoma, and liver failure that leads to transplantation. The current standard treatment, aExpand
  • 518
  • 34
  • Open Access
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
BACKGROUND A simple treatment regimen that is effective in a broad range of patients who are chronically infected with the hepatitis C virus (HCV) remains an unmet medical need. METHODS WeExpand
  • 700
  • 34
  • Open Access
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
BACKGROUND In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologicExpand
  • 582
  • 34
  • Open Access
Performance of transient elastography for the staging of liver fibrosis: a meta-analysis.
BACKGROUND & AIMS Transient elastography has been studied in a multitude of liver diseases for the staging of liver fibrosis with variable results. A meta-analysis was performed to assess the overallExpand
  • 1,272
  • 31
  • Open Access
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
BACKGROUND In this phase 3 trial we evaluated the efficacy and safety of the interferon-free combination of ABT-450 with ritonavir (ABT-450/r), ombitasvir (also known as ABT-267), dasabuvir (alsoExpand
  • 444
  • 26
  • Open Access
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
BACKGROUND Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct‐acting antiviralExpand
  • 300
  • 24
  • Open Access